- Home
- TARA vs MDXH Comparison
TARA vs MDXH Comparison
Compare TARA & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TARA | MDXH |
|---|---|---|
| Founded | N/A | 2003 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.5M | 167.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | TARA | MDXH |
|---|---|---|
| Price | $5.69 | $3.34 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | ★ $20.40 | $7.67 |
| AVG Volume (30 Days) | ★ 815.8K | 118.6K |
| Earning Date | 11-10-2025 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $103,069,000.00 |
| Revenue This Year | N/A | $23.34 |
| Revenue Next Year | N/A | $22.98 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 21.68 |
| 52 Week Low | $2.77 | $1.35 |
| 52 Week High | $7.82 | $5.33 |
Technical Indicators
Market Signals| Indicator | TARA | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 50.75 | 45.39 |
| Support Level | $5.03 | $3.20 |
| Resistance Level | $5.80 | $3.58 |
| Average True Range (ATR) | 0.30 | 0.21 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 67.86 | 49.00 |
Price Performance
Historical ComparisonAbout TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).
About MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.